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Opioid use disorder (OUD) is increasingly recognized as a
national public health epidemic in the United States, leading
not only to adverse perinatal outcomes, but also negative
effects on childhood neurodevelopment.1–5 The problem is
further compounded by the increasing burden of healthcare
costs associated with treatment of neonates exposed to
opioids in utero who then experience neonatal opioid with-
drawal syndrome (NOWS).6,7 Management algorithms of
OUD in pregnancy have traditionally hinged on the use of
methadone as the agent of choice for pharmacotherapy—
either constituted along the lines of a methadone “taper” or
maintaining a steady state of methadone as a form of
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Abstract Objective To examine the relationship between antepartum buprenorphine dose for
medication-assisted treatment (MAT) of opioid use disorder (OUD) and incident
neonatal opioid withdrawal syndrome (NOWS).
Study Design We performed a prospective cohort study of pregnant women with a
singleton gestation diagnosed with OUD and receiving buprenorphine for MAT at a
tertiary care academic institution from July 2015 to January 2017. We divided the study
cohort into two groups—pregnancies with versus without NOWS. Substance abuse
patterns in pregnancy, maternal, and neonatal clinical outcomes were compared.
Results The incidenceofNOWSwas31.11% (n ¼ 28/90) inour studycohort. Pregnancies
with NOWS had a significantly higher rate of benzodiazepine positive urine tests and
number of positive urine drug screen (UDS) results for illicit opioids. The group without
NOWS had significantly higher number of patients with an appropriate UDS result at
delivery through postpartum. Rates of neonatal intensive care unit (NICU) admission,
length of NICU stay, and maximum Finnegan score were significantly higher in the group
with NOWS. Neither the initial (10.6  5.2 versus 10.3  4.8 mg, p ¼ 0.80) nor the final
buprenorphine doses (13.3  5.1 versus 13.0  4.6 mg, p ¼ 0.81) were significantly
different between study groups.
Conclusion The occurrence of NOWS was not related to buprenorphine dose used
for MAT.
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medication-assisted treatment (MAT).8–10 However, the use
of methadone for MAT during pregnancy also carries the risk
of fetal exposure in utero, manifesting as NOWS, also known
as neonatal abstinence syndrome (NAS).10,11 Affected neo-
nates exhibit a clinical profile characterized by hyperirrit-
ability, agitation, and central and/or autonomic nervous
system dysfunction often necessitating intervention with
pharmacologic therapy. This in turn leads to prolonged
inpatient hospitalization for the neonate and the need for
continued outpatient surveillance.10–15 Recently, attention
has shifted toward the use of buprenorphine as an agent of
choice forMATof OUDs in pregnancy. Buprenorphine admin-
istration was initially targeted toward women who could be
followed-up at longer intervals, representing a higher level of
medication adherence and compliance, without the need for
daily monitoring (as is the case with methadone). Buprenor-
phine treatment in an office-based setting allows women to
have prescriptions for their medications, longer intervals
between visits, and unsupervised dosing representing a
model of care consistent with other chronic medical
illnesses, in contrast to methadone treatment that requires
more intensive monitoring with daily supervised dosing for
the first 90 days of treatment that sometimes becomes a
barrier to treatment entry.16–19 Importantly, maternal treat-
ment with buprenorphine in pregnancy has been shown to
have similar efficacy asmethadonewhile also representing a
safe and convenient option for outpatient management by
allowing for prescribing through certified physician offices
rather than daily attendance at methadone clinics.16,18,20,21
While buprenorphine is generally accepted in pregnancy as a
safe alternative to methadone for MAT, the extent to which
buprenorphine dose correlates with the risk of NOWS re-
mains incompletely understood, with some studies support-
ing a dose–response relation and others not.1,17,20–22
The objective of our studywas to examine the relationship
between antepartum buprenorphine dose among pregnant
women undergoing MAT for OUD and incident NOWS.
Methods
The study was approved by the Institutional Review Board
(IRB) at the University of Kentucky. Women were recruited
from the Perinatal Assistance and Treatment Home (PATH-
ways) Program at the University of Kentucky Polk Dalton
clinic—an outpatient treatment program that includes group
prenatal and postpartum care, MAT, and supportive services
for high-riskwomen throughout Kentucky.We prospectively
recruited and followed a cohort of pregnant women with a
well-documented history of OUD, receiving prenatal care at a
tertiary teaching institution from July 2015 to January 2017.
Inclusion criteria included: (1) current diagnosis of opioid
dependence with participation in the buprenorphine treat-
ment program; (2) less than 30 weeks with a singleton
gestation; and (3) age 18 to 49 years old. Women were
excluded if they had current prisoner status, current severe
mental illness (e.g., bipolar disorder with current mania,
current suicidal ideation), or alcohol or sedative/hypnotic
dependence that required medical intervention.
All patients received buprenorphine as the agent of choice
for MAT of OUD, which was prescribed by waivered
(X-licensed) maternal fetal medicine physicians with ad-
vanced training and licensure for buprenorphine adminis-
tration. Buprenorphine dosing was once daily after initial
buprenorphine induction, which verified objective with-
drawal with the Clinical Opiate Withdrawal Scale (COWS).
Medication adjustments were individualized for each patient
based on healthcare provider clinical judgment, factoring
in patient response and medication adherence. Patients
received no more than a 2-week prescription at any given
point in time. All patients received buprenorphine in the
form of the commercially marketed generic formulation—
Subutex (Reckitt Benckiser Pharmaceuticals, Inc, Richmond,
Virginia), containing only buprenorphine, without naloxone.
Pregnant patients with ongoing illicit drug use, e.g., as
determined by self-report and/or urine drug testing, were
managed by a customized approach centered upon escala-
tion of care. For example, patients received increased face-to-
face counseling with providers having subspecialty training
in maternal fetal medicine, mental health, and addiction
medicine. This was accompanied by closer follow-up and
surveillance monitoring with visits ranging from once to
thrice weekly. Patients were followed through delivery until
6 weeks postpartum. Patients underwent serial urine drug
screens (UDS) at each prenatal visit, upon admission into the
Labor & Delivery Unit and every postpartum visit. MAT was
continued in all cases through the study period. Upon
completion of the 6-week postpartum period, maternal
and neonatal clinical outcomes data were abstracted through
a review of their respective medical records. Data pertaining
to maternal demographics, patterns of antenatal substance
abuse, and incident pregnancy comorbidities were obtained
from a thorough review of their outpatient electronic med-
ical record. Labor and delivery–related outcomes were ascer-
tained through a review of the inpatient electronic medical
record system. The diagnosis of NOWS requiring pharmaco-
logic management was confirmed based on documentation
in the neonatal electronic medical record system. These cases
were managed as per standardized institutional neonatal
intensive care unit (NICU) protocols that used a modified
Finnegan scale for scoring neonates for opioid withdrawal,
also known as the MOTHER NAS scale.1,14 In this system,
scoring is done for any infant chronically exposed to opioids
in utero or who has demonstrated signs of significant with-
drawal. Scoring is performed every 3 to 4 hours and changed
to every 6 to 8 hours once the infant is stable. Pharmacologic
therapy was initiated when three consecutive scores were
>8 or two consecutive scores were >12. We divided the
study cohort into two groups—that is, pregnancies with and
without incident NOWS requiring pharmacotherapy.
Details of maternal substance abuse patterns during preg-
nancy, aswell asmaternal andneonatal clinical outcomes,were
compared across these twogroups, using the two-sample t-test
or Mann–Whitney U test for continuous data, as appropriate,
and the chi-square test of association or Fisher’s exact test for
categorical data. All statistical analyses were performed using
SAS version 9.4; an α level of 0.05 was used throughout.
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Results
We recruited a total of 96 patients receiving buprenorphine
for treatment of OUD in pregnancy. Of these, 90 patients
delivered at our tertiary teaching hospital andwere therefore
available for follow-up of maternal and neonatal outcomes
(the rest delivered at an outside hospital and hence their
delivery outcomes data and neonatal data were unavailable
and excluded from analyses). The incidence of NOWS was
noted to be 31.11% in our cohort (n ¼ 28). Demographic
characteristics (►Table 1) were similar among the group of
patients with and without incident NOWS. Interestingly,
patterns of tobacco use during pregnancy (including smok-
ing before and during pregnancy) as well as the use of
smoking cessation treatment with nicotine replacement
therapy were also similar in both groups (p > 0.05).
Substance abuse characteristics between the two groups
are compared in►Table 2. Patients in each group underwent
buprenorphine induction at 20 weeks gestation. Routes of
substance use or age at initiation of substancemisuse did not
differ between the two groups. The group with NOWS was
noted to have a significantly higher rate of benzodiazepine
abuse—as noted in their history of substance abuse as well as
detection at initial UDS. Significantly, pregnancies with
NOWSwere also noted to have a significantly higher number
of positive UDS results (for illicit substances) over the course
of pregnancy. Most importantly, neither the initial nor the
final buprenorphine dose at delivery was significantly dif-
ferent between the two groups.
►Table 3 compares maternal pregnancy and delivery
outcomes as well as postpartum course among the two study
groups. There were no significant differences in the inci-
dence of adverse perinatal outcomes between the study
groups. However, the group without NOWS had a signifi-
cantly higher number of patients with an appropriate UDS
result (i.e., only positive for buprenorphine) at delivery, 2, 4,
and 6 weeks postpartum. Rates of NICU admission, length of
NICU stay, and maximum Finnegan score were significantly
higher in the group with NOWS, as seen in ►Table 4. The
remainder of the neonatal outcomes under evaluation failed
to reach statistical significance.
Discussion
Within our clinical cohort, the occurrence of NOWS was not
related to the buprenorphine dose used for MAT of OUD in
pregnancy. Therewere no significant differences in the initial
or final buprenorphine dose in pregnancieswith andwithout
Table 1 Demographic characteristics
Total sample
(N ¼ 90)
Mean  SD,
Median (IQR)
or n (%)
NOWS
(n ¼ 28)
Mean  SD,
Median (IQR)
or n (%)
Non-NOWS
(n ¼ 62)
Mean  SD,
Median (IQR)
or n (%)
p
Age 28.8  4.6 28.6  5.1 28.9  4.4 0.79
Gravidity 3 (2–5) 3 (2–4.5) 3 (2–5) 0.98
Parity (living) 2 (1–3) 2 (1–2.5) 2 (1–3) 0.86
Living children parent custody 0 (0–1) 0 (0–0.5) 0 (0–1.0) 0.29
BMI at start of care 25.1  4.6 25.2  4.5 25.0  4.6 0.82
Race/ethnicity
White/non-Hispanic 83 (92.2%) 25 (89.3%) 58 (93.6%) 0.67
Other 7 (7.8%) 3 (10.7%) 4 (6.4%)
Partnered status
Yes 33 (37.1%) 10 (37.0%) 23 (37.1%) 0.99
No 56 (62.9%) 17 (63.0%) 39 (62.9%)
Employment
Employed 14 (15.6%) 1 (3.6%) 13 (21.0%) 0.056
Unemployed 76 (84.4%) 27 (96.4%) 49 (79.0%)
Nicotine replacement
Yes 20 (24.4%) 4 (15.4%) 16 (28.6%) 0.20
No 62 (75.6%) 22 (84.6%) 40 (71.4%)
Using tobacco at delivery
Yes 82 (92.1%) 26 (92.9%) 56 (91.8%) 0.86
No 7 (7.9%) 2 (7.1%) 8 (8.2%)
Abbreviations: BMI, body mass index; IQR, interquartile range; NOWS, neonatal opioid withdrawal syndrome; SD, standard deviation.
Note: p-Values represent comparison between the NOWS and non-NOWS group.
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incident NOWS. The incidence of NOWS in our cohort was
noted to be 31.11%, which is lower than the reported rates in
several other contemporary studies.1,23,24 The incidence of
NOWS requiring treatment in the setting of maternal bupre-
norphine use has been variably reported from 22 to 63%.21–26
Interestingly, several of these studies have focused on com-
paring the impact of methadone versus buprenorphine on
incident NOWS. Patterns of tobacco use, including ongoing
smoking and smoking cessation/nicotine replacement ther-
apy, were similar among patients with and without incident
NOWS in our study. This is in contrast to studies which show
a relationship between maternal tobacco exposure and an
increased likelihood of developing NOWS among women
undergoing MAT for OUD in pregnancy.27,28
In a double-blind randomized controlled trial called the
Maternal Opioid Treatment: Human Experimental Research
(MOTHER) project, Jones et al compared neonatal outcomes
among women undergoing MAT with methadone versus bu-
prenorphine at eight different international sites. They found
that neonates born to mothers receiving buprenorphine for
MAThadasignificantlyshorterdurationof treatmentofNOWS
and required significantly lesser morphine for treatment.1
However, the total number of neonates receiving treatment
for NOWS was not statistically different in the two groups in
this study. The incidence of treatment requiring NOWS in the
group receivingbuprenorphine in theMOTHERstudywas47%.
Globally, fewotherstudieshavedelvedinto theevaluationof
methadone versus buprenorphine and consequent develop-
mentofNOWS. Inanonrandomizedpopulation-basedSwedish
study, Kakko et al compared neonatal outcomes among pro-
spectively followed pregnancies exposed to buprenorphine
with retrospectively analyzed pregnancies exposed to
Table 2 Details of substance abuse patterns
Total sample
(N ¼ 90)
Mean  SD,
Median (IQR)
or n (%)
NOWS
(n ¼ 28)
Mean  SD,
Median (IQR)
or n (%)
Non-NOWS
(n ¼ 62)
Mean  SD,
Median (IQR)
or n (%)
p
Gestational age at program initiation 21.5  8.4 23.3  8.4 20.6  8.4 0.17
Gestational age at buprenorphine induction 21.2  8.1 22.1  7.6 20.8  8.3 0.53
Age at first substance abuse 18.7  5.0 18.5  5.9 18.8  4.4 0.80
History of substance abuse
Opioids 88 (97.8%) 28 (100.0%) 60 (96.8%) >0.99
Methamphetamine 17 (18.9%) 7 (25.0%) 10 (16.1%) 0.32
Cocaine 25 (27.8%) 9 (32.1%) 16 (25.8%) 0.53
Benzodiazepines 31 (34.4%) 13 (46.4%) 18 (29.0%) 0.11
THC 54 (60.0%) 19 (67.9%) 35 (56.5%) 0.31
Route of substance abuse
Oral 85 (94.4%) 26 (92.9%) 59 (95.2%) 0.65
Intravenous 43 (47.8%) 16 (57.1%) 27 (43.6%) 0.23
Intranasal 68 (75.6%) 26 (92.9%) 42 (67.7%) 0.015
Substances positive on initial UDS
Opioids 34 (37.8%) 11 (39.3%) 23 (37.1%) 0.84
Methamphetamine 7 (7.8%) 3 (10.7%) 4 (6.5%) 0.67
Cocaine 10 (11.1%) 6 (21.4%) 4 (6.5%) 0.065
Benzodiazepines 16 (17.8%) 10 (35.7%) 6 (9.7%) 0.006
THC 27 (30.0%) 12 (42.9%) 15 (24.2%) 0.074
Positive UDS (% yes) 69 (76.7%) 27 (96.4%) 42 (67.7%) 0.003
Number of positive UDS total
(any substance other than buprenorphine)
4 (1–8) 9 (6–12.5) 2 (0–6) <0.001
Positive UDS illicit opioids (% yes) 48 (53.3%) 23 (82.1%) 25 (40.3%) <0.001
Number of positive UDS total – illicit opioids 1 (0–3) 2 (1–4) 0 (0–2) <0.001
Initial buprenorphine dose 10.4  4.9 10.6  5.2 10.3  4.8 0.80
Final buprenorphine dose 13.1  4.7 13.3  5.1 13.0  4.6 0.81
Abbreviations: IQR, interquartile range; NOWS, neonatal opioid withdrawal syndrome; SD, standard deviation; THC, tetrahydrocannabinol; UDS,
urine drug screen.
Note: p-Values represent comparison between the NOWS and non-NOWS group.
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methadone. In this study, treatment with buprenorphine
offered the advantage of lower incidence of NOWS requiring
pharmacological treatment, as well as shorter length of hospi-
tal stay for affected neonates.23 In a similar study of a Norwe-
gian national clinical cohort of 139 mother–neonate couplets,
Welle-Strand et al compared neonatal outcomes among pa-
tients receiving methadone versus buprenorphine for MAT
during pregnancy. They found that the number of neonates
that received treatment for NOWSwas not significantly differ-
ent between both groups as was the case with the peak
Finnegan score and the length of treatment.24 Significantly,
in a subgroup analysis, this group found that the concomitant
benzodiazepines abuse during pregnancy while on MAT was
associatedwith longer duration of treatment for NOWS. These
findings parallel our observationwherein pregnancies affected
by NOWS appear to have a significantly higher rate of benzo-
diazepine abuse. This also points toward the contributory role
of concomitant illicit drug use (particularly benzodiazepine
abuse)onpossiblyalteringneonataloutcomesamongpregnant
women receiving MAT for OUD.
In a secondary analysis of the MOTHER study, Jones et al
examined the relationshipbetweenbuprenorphine atdelivery
among patients undergoing MAT and neonatal outcomes
includingNOWS.29Theauthors foundno relationshipbetween
buprenorphine dose and any of the neonatal outcomes under
study, including incident NOWS, gestational age at delivery,
Table 3 Maternal pregnancy course, delivery, and postpartum outcomes
Total sample
(N ¼ 90)
n (%)
NOWS
(n ¼ 28)
n (%)
Non-NOWS
(n ¼ 62)
n (%)
p
Preterm labor 11 (12.2%) 2 (7.1%) 9 (14.5%) 0.49
Preeclampsia 5 (5.7%) 1 (3.6%) 4 (6.7%) >0.99
Gestational hypertension 7 (7.8%) 1 (3.6%) 6 (9.7%) 0.43
Diabetes 6 (6.7%) 4 (14.3%) 2 (3.2%) 0.073
IUGR 10 (11.1%) 1 (3.6%) 9 (14.5%) 0.16
Oligohydramnios 1 (1.1%) 0 (0.0%) 1 (1.6%) >0.99
Polyhydramnios 1 (1.1%) 1 (3.6%) 0 (0.0%) 0.31
Hepatitis C 42 (47.2%) 14 (50.0%) 28 (45.9%) 0.72
RPR positivity 1 (1.1%) 1 (3.6%) 0 (0.0%) 0.31
Cholestasis 2 (2.9%) 2 (8.7%) 0 (0.0%) 0.11
Mode of delivery
Primary cesarean section 10 (11.1%) 3 (10.7%) 7 (11.3%) 0.78
Repeat cesarean section 29 (32.2%) 11 (39.3%) 18 (29.0%)
Assisted vaginal 2 (2.2%) 1 (3.6%) 1 (1.6%)
Spontaneous vaginal 48 (53.3%) 13 (46.4%) 35 (56.5%)
VBAC 1 (1.1%) 0 (0.0%) 1 (1.6%)
Induction of labor
Yes 24 (27.3%) 6 (22.2%) 18 (29.5%) 0.48
No 64 (72.7%) 21 (77.8%) 43 (70.5%)
Augmentation of labor
Yes 20 (27.4%) 6 (26.1%) 14 (28.0%) 0.86
No 53 (72.6%) 7 (73.9%) 36 (72.0%)
Appropriate UDS at delivery
Yes 59 (67.8%) 13 (46.4%) 46 (78.0%) 0.002
No 20 (23.0%) 13 (46.4%) 7 (11.9%)
Not done 8 (9.2%) 2 (7.2%) 6 (10.2%)
UDS appropriate at 2 wk postpartum (n ¼ 82) 60 (73.2%) 10/24 (41.7%) 50/58 (86.2%) <0.001
UDS appropriate at 4 wk postpartum (n ¼ 76) 54 (71.1%) 12/23 (52.2%) 42/53 (79.3%) 0.017
UDS appropriate at 6 wk postpartum (n ¼ 58) 33 (56.9%) 8/21 (38.1%) 25/37 (67.6%) 0.029
Abbreviations: IUGR, intrauterine growth restriction; NOWS, neonatal opioid withdrawal syndrome; RPR, rapid plasma reagin; UDS, urine drug
screen; VBAC, vaginal birth after cesarean section.
Note: p-Values represent comparison between the NOWS and non-NOWS group.
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Appearance, Pulse, Grimace, Activity, and Respiration (APGAR)
scores at 1 and 5minute, neonatal head circumference, length
and birthweight at birth, amount ofmorphine needed to treat
NOWS, duration of treatment, and length of neonatal hospital
stay. Based on these findings, this group failed to support the
occurrence of a dose–response relationship betweenmaternal
buprenorphinedose forMATandneonatal outcomes including
NOWS.Paralleling theseresults,wefailed to identifya relation-
ship between buprenorphine dose and NOWS. In our study
cohort, both the initial and final buprenorphine dose was
similar among pregnancies with and without the occurrence
of NOWS requiring pharmacologic treatment.
As a strength of our study, it prospectively followed
patients receiving buprenorphine for MAT of OUD in preg-
nancy to evaluate the impact on maternal and neonatal
outcomes, specifically NOWS. We also performed a detailed
evaluation of patterns of substance abuse in our study cohort
not only based on self-report but also ascertained through
objectivemetrics such as UDS testing. Urine drug testing was
performed throughout the course of pregnancy extending
through the 6-week postpartum study period, and also
included neonatal urine testing. Buprenorphine dosing was
also managed by a single provider with specialized training
and licensure with consultation provided as needed by an
addiction medicine psychiatrist.
This study has limitations—first, we did not plan a priori to
test the effect of varyingdose levels of buprenorphineonNOWS;
thus, we are unable to draw definitive conclusions about the
buprenorphine dose–response relationship with incident
NOWS. While the biologic plausibility of such a relationship
Table 4 Neonatal course
Total sample
(N ¼ 90)
Mean  SD,
Median (IQR)
or n (%)
NOWS
(n ¼ 28)
Mean  SD,
Median (IQR)
or n (%)
Non-NOWS
(n ¼ 62)
Mean  SD,
Median (IQR)
or n (%)
p
Gestational age at delivery 38.0  2.2 38.5  1.1 37.8  2.6 0.17
Baby gender
Male 43 (48.9%) 15 (53.6%) 32 (53.3%) 0.55
Female 45 (51.1%) 13 (46.4%) 28 (46.7%)
APGAR score at 1 min
< 7 9 (10.1%) 4 (14.8%) 5 (8.1%) 0.45
 7 80 (89.9%) 23 (85.2%) 57 (91.1%)
APGAR score at 5 min
< 7 6 (6.7%) 4 (14.8%) 2 (3.2%) 0.066
 7 83 (93.3%) 23 (85.2%) 60 (96.8%)
Birth weight (g) 2804.3  491.8 3013.6  350.4 2709.7  519.0 0.002
Birth weight percentile 27.6  20.3 38.5  23.2 23.4  17.5 0.003
Mode of feeding
Breastfeeding 17 (18.9%) 2 (7.1%) 15 (24.2%) 0.049
Bottle 48 (53.3%) 20 (71.4%) 28 (45.2%)
Combination 25 (27.8%) 6 (21.4%) 19 (30.7%)
NICU admission 42 (46.7%) 28 (100.0%) 14 (22.6%) <0.001
Days in NICU 6.5 (0–17) 16.5 (12.5–23.5) 0 (0–5.5) <0.001
Highest Finnegan score 11 (8–14) 14 (13–15) 9 (7–11) <0.001
Maximum morphine dose 0.15 (0.14–0.18)
Total number of morphine doses 97 (69–152)
Infant UDS positive for buprenorphine 68 (80.0%) 17 (63.0%) 51 (87.9%) 0.007
Infant UDS positive for norbuprenorphine 75 (88.2%) 22 (81.5%) 53 (91.4%) 0.19
Maternal screen positive for buprenorphine 51 (58.6%) 14 (51.9%) 37 (67.7%) 0.39
Maternal screen positive for norbuprenorphine 74 (85.1%) 20 (74.1%) 54 (90.0%) 0.10
Breastfeeding at discharge 31 (34.8%) 4 (14.3%) 27 (44.3%) 0.006
Abbreviations: APGAR score, Appearance, Pulse, Grimace, Activity, and Respiration score; IQR, interquartile range; NICU, neonatal intensive care
unit; NOWS, neonatal opioid withdrawal syndrome; SD, standard deviation; UDS, urine drug screen.
Note: p-Values represent comparison between the NOWS and non-NOWS group. All bold represents statistical significance at the 95% confidence level.
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seemsappropriate, thecurrentdataare inadequate inaddressing
this question from an evidence-based standpoint. However, in
ourstudy, thebuprenorphinedosewas titrated toadminister the
most clinically appropriate dose on an individualized basis
factoring in patient symptomatology and drug response, med-
ication compliance, and UDS results. Hence, we were unable to
specifically study the effect of varying dose levels. Similarly,
group comparisons were not planned according to a specified
level of statistical power, and post hoc power analysis is not
valid.30 Future studies in this area may benefit from larger
sample sizes for more powerful group comparisons. Second,
alterations in buprenorphine dose were individualized, as
against adopting a protocolized approach. Given the sheer
paucity of data on alterations of buprenorphine metabolism
over the pregnancy time course, we chose to adopt an indivi-
dualized approach to identify the dose that best suited each
patient’s needs. Lastly, we are unable to comment on a compar-
ison with methadone, since this was beyond the scope of this
study. However, our data support the safety for adjusting the
antepartum buprenorphine dose as deemed clinically appro-
priatewithminimalneonatal adverseeffects. Interestingly, there
are inconsistent data regarding the relationship between
antenatal buprenorphine dose in pregnancy for MAT and the
severity of NOWS.21,25,26 In an attempt to elucidate the biologic
relationship between maternal buprenorphine and dose and
incident NOWS, previous research has examined the levels of
buprenorphineand itsmetabolites intheurineandmeconiumof
infants born to mothers receiving buprenorphine during preg-
nancy.31,32 However, these studies provide limited insights into
the plausibility of a relationship between antenatal buprenor-
phine dose and incidentNOWS. In the light of thesefindings, our
study aimed at examining the relationship between buprenor-
phine dose and incident NOWS among pregnant patients
receiving buprenorphine for MAT of OUD during pregnancy.
Based on our data, we are not able to establish a diagnosis of a
relationship between buprenorphine dose in pregnancy and
subsequent NOWS. However, our results suggest that women
who are able to undergoMATwith buprenorphine in pregnancy
without the concurrent use of illicit opioids or benzodiazepines
are much less likely to have adverse neonatal outcomes as
comparedwith theircounterparts. This is important information
for clinicians treating patients for OUD in pregnancy. Further
studies—particularly, larger randomized prospective trials—are
warranted to evaluate if a dose–response relationship exists
between antenatal buprenorphine dose and the occurrence and
severity of incident NOWS in pregnant patients undergoing
MAT of OUD.
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